Sanofi
Anti-CEACAM5 antibodies and uses thereof

Last updated:

Abstract:

Disclosed are antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also disclosed are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and pharmaceutical compositions comprising the antibodies or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.

Status:
Grant
Type:

Utility

Filling date:

3 Sep 2019

Issue date:

17 May 2022